Key result
Sacubitril/valsartan induced a super-response in 35.1% of ambulatory heart failure patients, which could be predicted by a simple clinical score with an AUC of 0.720.
Why the study?
Response to sacubitril/valsartan varies among heart failure patients and its clinical implementation has been slow, prompting the development of a predictive score for super-responders.
Can a clinical score predict super-response to sacubitril/valsartan in ambulatory patients with heart failure with reduced ejection fraction?
Population
185 consecutive heart failure outpatients prescribed sacubitril/valsartan from two tertiary hospitals
Design
Retrospective analysis with internal bootstrap validation
Follow-up
12-month
Authors
Loading...
May aid selection of ambulatory HFrEF patients for sacubitril/valsartan; leaves open prospective validation before practice change.
Observational (n=185)
Yes
Can a clinical score predict super-response to sacubitril/valsartan in ambulatory patients with heart failure with reduced ejection fraction?
Effect estimate: AUC 0.720 (95% CI 0.644-0.797)
The AWARD-Class score is a simple clinical tool that can identify ambulatory heart failure patients who are highly likely to be super-responders to sacubitril/valsartan therapy at 1 year.
Moliner‐Abós et al. (2021) conducted an observational in Heart failure with reduced ejection fraction (n=185). Sacubitril/valsartan was evaluated on Super-response to sacubitril/valsartan (no HF admissions, death, or heart transplant, and ≥50% reduction in NT-proBNP and/or ≥10 points increase in LVEF) (AUC 0.720, 95% CI 0.644-0.797). Sacubitril/valsartan induced a super-response in 35.1% of ambulatory heart failure patients, which could be predicted by a simple clinical score with an AUC of 0.720.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: